The running title: History dependent effects of GR antagonism after SPS
Introduction
Acute responses to stress are aimed to restore homeostatic balance, but chronic or severe stressors may involve a change in homeostatic set points, in a process that has been called allostasis (McEwen, 2001 ). In such situations the organism will structurally require more, or other resources maintain homeostasis (Chrousos, 2009; de Kloet et al., 2005; Joels and Baram, 2009 ). Moreover, when a stress response is, for any reason, too strong or lasts too long the outcome can become maladaptive, increasing the risk for disease in many systems, including psychopathologies (Juruena, 2014; van Campen et al., 2014) .
Diverse stressors activate a wide spectrum of interacting hormonal and neuronal systems resulting in behavioral and physiological responses (Fuchs and Flugge, 1998) , such as adrenal corticosteroid hormone release. In the brain corticosteroids affect neuronal excitability and structure via binding to high affinity mineralocorticoid receptors (MR) and lower affinity glucocorticoid receptors (GR) . The GR in particular is considered as the mediator of maladaptive effects of excessive corticosteroid exposure, including vulnerability to psychiatric disease (Castro-Vale et al., 2016) . This may be the case in early life stress and adult traumatic experience, which both can increase vulnerability and/or lead to posttraumatic stress disorder (PTSD) in some individuals.
Disorders like PTSD are characterized by impaired abilities to use contextual information (safety cues) in a situation of potential threat (Ehlers and Clark, 2000; van Ast et al., 2012) , or impaired abilities to acquire and express inhibitory memory (Jovanovic et al., 2013; Jovanovic et al., 2010a; Jovanovic et al., 2010b) . This then may result in enhanced expression of fear.
Several studies have shown that administration of the GR antagonist RU38486 (RU486/Mifepristone) can block the acute effects of stress on memory and impairs formation of aversive memory such as contextual fear conditioning when administered shortly after training (Pugh et al., 1997; Zhou et al., 2010) . However, in psychopathological settings, reversal of established maladaptive responses would be needed. Strikingly, recent studies demonstrated that RU486 treatment during adulthood normalized effects of early life stress in male rats, including deficits in contextual memory, changed neuronal activity and enhanced freezing behavior (Arp et al., 2016; Loi et al., 2017) . Similar findings were obtained after stress in adolescence (Papilloud et al., 2018) . Although RU486 also is a potent antagonist of the progesterone receptor, and a weak antagonist for the androgen receptor (Gaillard et al., 1984) , all these effects are generally assumed to reflect interference with GR signaling.
A C C E P T E D M A N U S C R I P T
Here we aimed to evaluate the potential of RU486 to reverse stress-induced changes in an animal model of adult stress. We employed the single-prolonged stress (SPS) model as a multimodal stress exposure protocol for traumatic memories in rats. SPS induces changed behavioral reactivity (Han et al., 2017) and has been proposed to model aspects of PTSD . Using a factorial design, we evaluated the effects of RU486 on the behavioral and neuroendocrine consequences of SPS. To underpin these observations, we examined gene expression in the paraventricular nucleus (PVN) of hypothalamus, hippocampus and amygdala. We measured expression of c-fos as a marker for neuronal activity, corticosteroid receptors, drivers of the stress response ((Crh, Avp) and genes that have been (epi-)genitally linked to PTSD (e.g. Pacap, Fkbp5).
Materials and methods

Animals
32 adult male Wistar rats (200-220 g, 7 weeks old) were obtained from China Medical University Animal Centre to make four experimental groups of n = 8. Rats were housed (two per cage) under controlled conditions of temperature and fixed light-dark cycle (22 ± 1 °C, 12h light/dark cycle, lights on at 7:00-19:00) with free access to standard food and tap water. All experiments were approved by the China Medical University Animal Care and were performed in accordance with the National Guideline on Animal Care.
Single prolonged stress (SPS) model
SPS was performed as previously described . The protocol consisted a 2-h immobilization period, in an acrylic animal holder, which was immediately followed by a 20 min forced swim in a plexiglass cylinder (50 cm height, 24 cm diameter) filled with 24°C fresh water (water depth: 40 cm). Rats were allowed to recuperate for 15 min and then were exposed to ether vapors until loss of consciousness. After recovery, the animals were then returned to their home cage and left undisturbed for 7 days (to allow PTSD symptoms to develop). Control animals remained in their home cage with no handling and were injected at the same time as the stressed groups.
Drugs
Mifepristone (RU486, Sigma, USA) was dissolved in DMSO (Beyotime, China) and diluted into 0.9% saline (20% DMSO) immediately before intraperitoneal injection (30 mg/kg).
Vehicle injections were saline containing 20% DMSO. The dose and DMSO concentration were performed by previously study (Bohacek et al., 2015; Taubenfeld et al., 2009 ).
Experimental design
The design is depicted in figure 1. Animals were given 1 week of habituation after arrival in the vivarium. Body weight was first determined 3 days before SPS using electronic weighing scale. The rats were then randomly assigned into two groups: SPS or control (16 animals per group). On day 0, rats received SPS exposure, or remained in their home cage. The SPS procedure took place in a different room, and was not witnessed by control rats. On days 8, 9
and 10 the animals from both groups received intraperitoneal injection of RU486 (30mg/Kg), or vehicle leading to 4 groups of 8 animals. One animal from the SPS plus RU486 group died during the forced swim experiment, probably from cardiac arrest. After the injections the animals were left undisturbed until day 14, when behavioral experiments were performed, with the exception of a tail bleeding for corticosterone and body weight measurements on day 11. Animals we sacrificed one day after behavioral testing in the morning.
Plasma corticosterone measurement and body weight measurement
Blood was collected from tail in Lithium Heparinized micro tubes (#20.1282, Saestedt, Germany) on day 1, 7, 11 and centrifuged at 2000g for 5min at 20 °C to obtain the plasma and then stored at -70 °C. Tail blood samples were collected between 9:00-10:00 and, between 19:00-20:00. At sacrifice, we collected trunk blood between 10:00-11:00. Corticosterone levels were determined with an ELISA assay kit (AC-15F1, Immunodiagnostic Systems, UK) according to the manufacturer's instructions. Body weight was determined using weighing scale on day -3, 1, 3, 7, 11. Body weight on day -3 as the baseline was 222 ± 10 g on average.
We expressed as the percentage weight of the increase relative to baseline.
Open-field (OF) test
The open-field test was used to study anxiety/fear-related behavior. The procedure was done as previous described (Han et al., 2014) . The apparatus was surrounded by black walls 40 cm in height, and the floor was 90 cm × 90 cm, subdivided into central (18 cm far from the wall) and peripheral compartments. During the experiment, each rat was put in the corner of A C C E P T E D M A N U S C R I P T apparatus, and permitted to explore freely for 5 min. Each trial was recorded by an automatic analysis system (Smart 3.0, Panlab, Barcelona, Spain). Total distance and time in the centre compartment were recorded. Total distance was used as locomotor activity. Percentage of time in the central compartment was used as parameter to assess anxiety-related behavior. The apparatus was cleaned with 10% ethanol before the introduction of each rat.
Elevated plus maze (EPM) test
The EPM apparatus consists of a plus-shaped maze elevated (80 cm) from the floor with two oppositely positioned closed arms (50 cm×10 cm, the walls are 30 cm high), two oppositely positioned open arms (50 cm×10 cm), and a center area (10×10 cm). Rats were placed in the central area of the maze, facing an enclosed arm, and permitted to explore freely for 5 min. 
Fear-condition test
Training test was performed as described previously (Han et al., 2017) . Rats were placed in the conditioning chamber (23 × 23 × 35 cm) for 2 min with white noise (background, 60 dB).
After a 2 min habituation period, an auditory cue (conditioned stimulus (CS), 2000 Hz, 80 dB) was presented for 30 s and an electrical foot shock (unconditioned stimulus (US), 2 s 1.5 mA) stimulation was delivered continuously during the last 2 s of the auditory cue. This presentation of CS-US repeated five times per session with a 30 s interval during each repeat. 30s after the last shock the rats were returned to home-cage (figure 4g).
We measured the short-term fear memory. Two hours after training, animals were placed in this chamber and tested for freezing (Barreiro et al., 2013; Goodfellow and Lindquist, 2014) .
After 2 min exploration (pre-CS) with white noise (background, 60 dB), the tone (CS, 2000 Hz, 80 dB) was presented for 30s without a foot shock. The behavior was recorded for another 90s, after which the rat was put back in its home-cage (figure 4i). The freezing activity was recorded and measured using Packwin 2.0 software (Panlab, Barcelona, Spain). Freezing time was used as an index of fear conditioning. Freezing was defined as immobility, excluding respiratory movements with a freezing posture more than 2 s. The chamber was cleaned using 10% ethanol after each animal. Frozen brains were sliced into 60 µm coronal sections. To collect the PVN, amygdala and dorsal hippocampus, punches were made using a 1.00 mm sample corer (Fine Science Tools, Foster City, CA, USA). RNA isolation, cDNA synthesis and qPCR was performed as described previously (van Weert et al., 2017) . Tested genes and their primers are described in Table 1 .
The relative expression of the target gene was calculated based on the threshold cycle (Ct). The ΔΔCt method was used to determine differences between groups.
Statistical analysis
The results were expressed as Mean ± SEM. Two-way ANOVA analysis of the data was performed with SPSS 23.0 to determine main effects of treatment. Turkey's post-hoc test was used to assess significant post-hoc differences between individual groups. Unpaired t test was performed during only two group data. Differences with P-values below 0.05 were considered statistically significant.
Results
A stress x RU486 interaction in reduction of body weight
On day 1, 3 and 7, after stress and before injection of RU486, the SPS rats gained less weight than the control animals (t = 9.54, p < 0.05; t = 4.09, p < 0.05; t = 6.50, p < 0.05; Figure 2a -d).
After drug treatment, the percentage body weight gain showed an effect of stress and an interaction between stress and RU486 on day 11 (F(1,25) = 44.10, p < 0.05; F(1,25) = 4.69, p < 0.05, Figure 2e ) and on day 14 (F(1,25) = 28.50, p < 0.05; F(1,25) = 5.65, p < 0.05, Figure 2f ). Post hoc analysis showed that in vehicle-treated SPS rats the percentage body weight gain increased and normalized towards unstressed rats on day 14. In contrast, RU486 treated rats still had a decreased percentage of body weight gain on day 11 and on day 14. These findings indicate that stress had a transient effect on body weight and that RU486 can attenuate body weight gain, but only did so in the context of prior stress exposure.
Plasma corticosterone level
Trough or AM corticosterone levels of the control rats were in the normal range (< 50 ng/ml).
Control rats PM levels were high relative to the normal range on day 1 and lowered over time to reach 200 ng/ml on day 11 (Atkinson et al., 2006) . On day 1 and 7 the SPS rats had elevated
AM corticosterone levels compared to the control rats (t = 4.38, p < 0.05; t = 2.44, p < 0.05; Figure 3a and Figure 3c ). In contrast, evening corticosterone (PM) levels were significantly decreased in SPS rats compared to control rats (t = 2.17, p < 0.05; t = 2.35, p < 0.05) ( Figure   3b and Figure 3d ). Therefore, SPS led to an apparent flattening of corticosterone rhythm. After drug treatment, morning corticosterone levels on day 11 tended to be suppressed by RU486, irrespective of stress history (F(1,23) = 3.439, p = 0.077) (Figure 3e ). On day 11, the afternoon corticosterone levels showed a significant effect of stress (F(1,24) = 17.14, p < 0.05) and a significant interaction between stress and RU treatment (Interaction, F(1,24) = 7.668 p < 0.05).
Specifically, 11 days after the stress, PM corticosterone levels were clearly elevated in vehicletreated SPS rats, while prior RU486 treatment normalized these values towards control levels ( Figure 3f ). On day 15, the trunk plasma corticosterone levels were consistent with the results on day 11 as RU486 treatment lead to normalization of corticosterone levels towards control levels (treatment, F(1, 26) = 19.25, p < 0.05) ( Figure 3g ). These results indicate that in vehicle treated SPS rats, there was a trajectory from an initially blunted circadian HPA axis activity towards an overall elevated activity (with the caveat that the animals received three injections on days 8-10), and that RU486 had both intrinsic and history-dependent effects that led to normalization of the axis towards control animals.
Behavioral reactivity in anxiety and fear freezing
Open-field test: partial reversal of stress effects by RU486
In the Open Field test there were no differences between the four groups for total distance walked, i.e. locomotor activity was very similar (Figure 4a ). Data for time spent in the central area showed main effects for stress and RU486 (stress, F(1, 27) = 14.578, p < 0.05; RU486 treatment, F(1, 27) = 5.089, p < 0.05; Figure 4b ). SPS led to reduced time in the central area, while RU486 lead to increased time in the central area. Although there was no formal interaction effect, post-hoc analysis showed that animals from the SPS Vehicle group spent significantly less time in the central area in comparison with Ctrl Vehicle group, but that RU486 treated SPS rats did not differ from non-stressed animals. These data indicate that RU486 was able to overcome some of the SPS-induced changes in behavioral reactivity.
Elevated Plus Maze test: independent effects of stress and RU486
In the elevated plus maze test there were no differences for total distance and the number of center crossings ( figure 4c -4d ). This indicates that the locomotor activity was similar for all There was no interaction between SPS and RU486. These latter data indicate that RU486 had a long lasting (days) effect on behavioral reactivity irrespective of stress-history.
Fear conditioning test: effects of RU486 on acquisition
During the acquisition phase (Figure 4g ), animals consistently froze following the shock.
Freezing time during acquisition was lower after RU486 treatment for all phases following the first shock (during shock: F(1, 27) = 7.327, p< 0.05; during intervals (F(1, 27) = 14.01, p< 0.05, Figure 4h ) and during the whole training time (F(1, 27) = 11.47, p< 0.05 figure 4h). These data indicate that RU486 affected the acquisition phase of the fear conditioning, irrespective of prior stress history.
During re-exposure two hours after training (Figure 4i ), the percentage of freezing time in the 120s exploration, the data showed that RU486-treated groups had a significantly decreased percentage freezing time compare vehicle groups (treatment, F(1, 27) = 5.08, p < 0.05, Figure   4j ). This is in line with a reduced freezing during the acquisition phase. In the total time of the re-exposure period, the percentage time spent also was significantly lower in RU-treated animals compared to vehicle treated groups (F(1, 27) = 4.22, p < 0.05, Figure 4k ). These data indicate that RU486 treatment effect the fear memory acquisition and that this effect likely underlies decreased responses to re-exposure in the short term fear memory setup.
qPCR results
In order to find correlates for endocrine and behavioral changes, we determined gene expression in punches from the PVN (Figure 5k-5l) , the dorsal hippocampus and the amygdala. C-fos mRNA was determined as a proxy for neuronal (re-)activity. Of note, these were basal c-fos mRNA levels, in the morning one day after behavioral testing. We determined expression of MR, GR as potential mediators of corticosterone effects. Crh and Avp expression was measured, given their role in driving the HPA axis. Fkbp5, Pacap and the gene coding for the PACAP receptor (Pac1) were included based on human genetic studies implicating these genes in the pathogenesis of PTSD (Klengel et al., 2016; Stevens et al., 2014) . In no areas did we observe changes in PAC1, FKBP5, MR, AVP and CRH mRNA two weeks after SPS (not shown in figures; AVP and CRH mRNA (figure 5j) was only measured in PVN).
In the PVN, c-fos mRNA levels were increased in the SPS group (F (1, 27) = 10.239, p < 0.05) and decreased in the RU486 group (F(1, 27) = 6.786, p < 0.05, Figure 5a ). There was a trend towards an interaction, in that RU486 clearly suppressed basal c-fos mRNA expression in
control rats, but not in SPS animals. In the amygdala we observed no changes in c-fos mRNA (Figure 5b) , while in the dorsal hippocampus there was an effect of RU486, and an interaction between stress and RU486 (F (1, 27) = 5.837, p < 0.05). Here, c-fos mRNA level in SPS/RU486 group was higher than SPS/Vehicle group. This indicates that RU486 selectively led to increased basal c-fos mRNA levels in the hippocampus stressed rats (figure 5c).
In the PVN, PACAP mRNA levels were suppressed after RU486, but only in control rats (Figure 5d ), mirroring the picture of c-fos mRNA. In the amygdala PACAP mRNA was decreased after stress, irrespective of RU486 treatment (Figure 5e ). In the dorsal hippocampus, PACAP mRNA was higher after SPS, without an effect of RU486 (Figure 5f ).
For GR mRNA changes tended to be modest in effect size. In the PVN GR mRNA was lower after SPS (Stress, F (1, 27) = 7.137, p < 0.05, Figure 5g ). In the amygdala, there was an interaction between stress and RU486, in that RU486 modestly suppressed GR expression only in the SPS rats ( Figure 5h ). In the hippocampus no changes in GR mRNA were observed (Figure 5i ).
The mRNA expression indicates that two weeks after SPS and 5 days after RU486 treatment (and after behavioral testing), there are substantial changes in basal c-fos and PACAP mRNA expression, and modest changes in GR expression. These changes vary strongly by brain area and may occur either independently for SPS and RU486, or in interaction.
Discussion
In this study we evaluated the effects of RU486 treatment one week after rats were exposed to the three consecutive stressors of the SPS model. We timed this intervention based on the many effects one week after the SPS procedure that have been reported in the literature (Lisieski et al., 2018; Souza et al., 2017) . The effects of treatment were evaluated again several days later.
We found that GR antagonism had intrinsic effects on fear behavior, the HPA axis and gene expression in the brain. These effects reveal a role of GR in normal (or naïve) homeostatic processes. Moreover, RU486 interacted with stress history, in that it was able to reverse a number of stress induced changes. These effects reveal a role of GR in stress adaption over days -weeks, or allostatic processes.
It is clear from the clinic and many animal models that GR can contribute to disease processes in many different body systems (Green et al., 2006; Koorneef et al., 2018; Roerink et al., 2016; Skor et al., 2013) . The effects of RU486 in interaction with earlier stress experiences actually show that GR is part of maintaining an altered state of homeostatic control for days or weeks after stress. Corticosteroid signaling has been considered a A C C E P T E D M A N U S C R I P T cornerstone of such allostatic adaptation (McEwen, 1998a, b) , but to which extent this is the case can only be revealed by blocking GR signaling. The most basic example of such 'acquired GR dependence' in our data is perhaps the effect of RU486 on body weight gain.
While SPS caused the expected reduction in body weight, this normalized after two weeks. RU486 blocked this normalization, which suggests that the restoring / maintaining normal body weight after stress depended on GR signaling, while in control rats GR signaling apparently had no role in maintaining body weight. This is reminiscent of the role of glucocorticoids during adolescence and puberty to promote ponderal growth (Romeo et al., 2006) . RU486 was previously shown to partially normalize effects induced by early life stress (ELS), in particularly enhanced fear learning (Arp et al., 2016; Loi et al., 2017) . ELS also can act as a 'second hit' in neurodegenerative mice models, and also here RU486 can have beneficial effects (Lesuis et al., 2018) . GR targeting also proved effective in reinstating hippocampus neurogenesis when given in the last days of a chronic stress paradigm (Mayer et al., 2006; Zalachoras et al., 2013) . Here, we extend these data to (reversal) effects by RU486 treatment one week after a single stress experience in adulthood. Of note, these reversal effects of RU486 occurred without reinstatement of the stressful context (save handling and injection), which is in contrast to the use of GR agonists in treatment of trauma or phobia (de Quervain et al., 2011) .
HPA axis
Corticosterone levels in SPS animals revealed a trajectory from an initially blunted circadian HPA axis activity towards an overall elevated activity. In particular on day 11, some rats in the two vehicle groups showed high corticosterone plasma levels. This likely reflects stress that was induced by the sampling procedure. These elevations did not occur in RU486 treated rats -and the effect of RU486-treatment may therefore reflect stress reactivity rather than true basal levels. Initially, SPS was reported to enhance glucocorticoid feedback sensitivity 7 days after stress, which was attributed to changed MR and GR expression (Liberzon et al., 1999) . The lower PM peak levels are in line with a GR-dependent increased feedback sensitivity, while the increased basal trough levels would classically suggest lower MR-mediated feedback (Dallman et al., 1989; Ratka et al., 1988) . In addition, the changed circadian rhythm may well reflect changed central drive to the axis. Disrupted circadian patterns of CORT may result in a 'sluggish' HPA axis response (Jacobson et al., 1988) , Rhythmicity of the HPA axis is A C C E P T E D M A N U S C R I P T essential for normal homeostatic control (Tsang et al., 2016) , and has been linked to psychopathology in the clinic (Adam et al., 2006; Wahbeh and Oken, 2013) .
Of note, our data suggest that the HPA axis is still in the process of regaining a new set point, because after day 7, PM levels became elevated. We cannot exclude that this change in trajectory may be caused by the injection paradigm. Regardless, RU486 suppressed PM corticosterone levels in SPS rats, without affecting levels in control rats. In contrast to the effect of RU486 on body weight, corticosterone levels were reversed to normal by RU486. Acute and single RU486 exposure disinhibits the HPA axis in rodents (Ratka et al., 1988) , and in humans this remains the case for at least 7 days (Block et al., 2018) . In rodents, the effects of several days of RU486 treatment vary, and can lead to suppression rather than disinhibition of the axis (Dalm et al., 2018) . The mechanism for suppression is unknown, but may involve pharmacokinetic aspects (shorter half-life in rodents and 'rebound' effects after RU486 clearance while corticosterone is still elevated, changes in brain penetration), or differences in partial agonism of RU486 (Meijer et al., 2005) . The present data suggest that indeed, in SPS rats, RU486 treatment can lead a normalization of basal corticosterone levels.
Behavior
In all three behavioral tests, RU486 had effects that were independent of SPS exposure. SPS 14 days earlier only affected behavior in the open field test, and -although there was no formal interaction -the combined stress and RU486 effects led to behavior of SPS-RU486 animals that was similar with control rats. The SPS procedure has previously been shown to have behavioral consequences after 7 days, including the open field test , elevated plus maze (Serova et al., 2014) and strength of fear conditioning (Iwamoto et al., 2007) . One study reported that normalization of effects 14 days after SPS (Wu et al., 2016) .
We found that some of the presumed changes in stress induced behavioral reactivity had normalized after 14 days, but that open field behavior still indicated increased anxiety. We used sequential analysis with three behavioral setups, which may have resulted in carry over effects between tasks and may have masked differential reactivity in for example the elevated plus maze. The effects of RU486 may be mediated via changed activity of the HPA axis. However, they also occurred in control animals where there were few changes in corticosterone level. RU486 effects may therefore also reflect changes in the brain regions important for appraisal and fear processing, including hippocampus and amygdala (Kim and Fanselow, 1992; Kim et al., 1993; Phillips and LeDoux, 1992) . The effect on acquisition in the fear conditioning paradigm precludes strong conclusions about fear related memory
formation (that is strongly affected by acute post training RU486 treatment (Oitzl and de Kloet, 1992; Pugh et al., 1997; Roozendaal et al., 2006; Sandi and Rose, 1994a, b) .
Gene expression in the brain
Given that the GR is a transcription factor, it seems reasonable to assume that the effects of RU486 on endocrine and behavioral (re)activity depend on changes in gene expression. We evaluated expression of a limited number of genes in three brain regions that may be involved in these effects (Adamec et al., 2005; Belda et al., 2008; Osterlund and Spencer, 2011; Weiss, 2007; Yehuda, 1997) . C-fos was taken as a measure for neuronal activity (Kovacs, 1998) PACAP has emerged as a key regulator of the stress response (Hashimoto et al., 2011; Mustafa, 2013; Tanida et al., 2010) . The PACAP expression in PVN mirrored c-fos expression, but directionality of this association remains unknown. Amygdala PACAP mRNA expression was lower after SPS and remained so after RU486 treatment, indicating changes in the brain even 14 days after stress exposure. In contrast, in the hippocampus PACAP expression was increased.
RU486 was without effects in amygdala and hippocampus. The PACAP receptor gene, PAC1
did not show differences between any of the groups. We conclude that PACAP gene expression shows substantial plasticity, but that also outspoken regional specificity.
GR mRNA expression showed small history-dependent changes in PVN and amygdala, while other genes did not show differences, (PVN AVP/CRH, FKBP5, MR). Therefore, many of the previously reported changes -mainly after 7 days -are likely to be transient. However, it is also clear from our data that at 14 days after SPS behavioral and endocrine responses and brain gene expression have not fully normalized. It will be interesting to further study the trajectory of adaptive changes during the first two weeks after SPS and beyond. It will also be of interest to vary frequency and timing or RU486 treatment. Given that RU486 had effects in naïve rats, treatment before the stressor may also change the trajectory of stressor-induced changes.
Moreover, it will be of interest to see whether newer more selective antagonists and GR modulators will have similar effects Pineau et al., 2016; Zalachoras et al., 2013 ).
In conclusion, the GR antagonist RU486 led to history-independent and history-dependent effects when applied one week after the single SPS procedure and tested several days after treatment. The latter demonstrate that in the state of post-SPS the GR-dependence of homeostatic processes has changed and in this way suggest that GR is part of allostatic regulation after adult stress. The fact that a number of SPS-induced changes were normalized after RU486 treatment reinforces the potential of targeting GR for treatment of stress-related psychopathologies.
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